menu
    • menu

    Company profile for The Progeria Research Foundation

    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    USP reference standards; highly characterized specimens of drug substances, impurities, excipients, degradation products & more.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Guizhou Utide Biotechnology Co., Ltd. - Specialized GMP manufacturing for next-generation GLP-1 peptide APIs.

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Progeria is a rare, fatal, “rapid aging” disease. Without the discovery of new treatments, all children with Progeria will die of heart disease at an average age of 14 years. The Progeria Research Foundation (PRF) was founded in 1999 in response to the complete lack of progress being made to help children with Progeria. Our mission: to discover, treatments and the cure for Progeria and its aging-related conditions, includi...
    Progeria is a rare, fatal, “rapid aging” disease. Without the discovery of new treatments, all children with Progeria will die of heart disease at an average age of 14 years. The Progeria Research Foundation (PRF) was founded in 1999 in response to the complete lack of progress being made to help children with Progeria. Our mission: to discover, treatments and the cure for Progeria and its aging-related conditions, including heart disease. Today, PRF continues to be the only organization in the world solely dedicated to this mission.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    The Progeria Research FoundationUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    PO Box 3453 Peabody, MA 01961-3453
    Telephone
    Telephone
    (978) 535-2594
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.progeriaresearch.org/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/the-progeria-research-foundation
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/Progeria

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    PBP World Meeting

    Not Confirmed

    envelop Contact Supplier

    PBP World Meeting

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Progeria Foundation, Forge Biologics Partner on Gene Therapy
    Progeria Foundation, Forge Biologics Partner on Gene Therapy

    03 Mar 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260303556687/en/The-Progeria-Research-Foundation-and-Forge-Biologics-Announce-Manufacturing-Partnership-to-Advance-Gene-Therapy-for-Children-with-Progeria

    BUSINESSWIRE
    03 Mar 2026
    Share Share
    FDA Approves Clinical Trial For New Progeria Treatment
    FDA Approves Clinical Trial For New Progeria Treatment

    02 Oct 2024

    // ACCESSWIRE

    https://www.accesswire.com/926833/us-fda-authorizes-launch-of-clinical-trial-to-support-new-treatment-development-for-progeria

    ACCESSWIRE
    02 Oct 2024
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search